Coming out of Covid, the vaccine market appeared to experience a renaissance as the innovations of the pandemic unleashed new ...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Coherus is resuming the supply of its ...
Aurinia Pharmaceuticals is reducing 45% of its workforce and is bringing in a new board member as part of a broader restructuring. The company ...
Plus, news about ADC Therapeutics, Celldex and Viracta Therapeutics: Geron inks up to $375M royalty and debt deal: The company now has a $125 million deal ...
Genmab is culling a trio of early oncology assets to focus on upcoming milestones for its late-stage programs that ...
Denali revealed new topline data Wednesday for an early-stage program that's a part of the FDA’s Operation Warp Speed for rare diseases. The program, DNL126, is an ...
Demis Hassabis is pursuing one of the boldest efforts of bringing AI into biotech, building out the Alphabet-backed startup Isomorphic Labs over the past three ...
After a year of customer pullbacks, biologics CDMO Avid Bioservices will be taken private by GHO Capital Partners and Ampersand Capital Partners in a deal worth $1.1 billion. “In evaluating ...
While there’s a lot of potential for AI in health tech, it will soon be commoditized, investor Greg Yap told Endpoints News in an interview on the sidelines of the ...
Gilead said its Covid-19 antiviral Veklury had $692 million in third-quarter sales, far more than the $270 million Wall ...
Joe Jimenez's Aditum Bio, an investment firm that builds companies around in-licensed assets, is going after one of the hottest new areas for its latest startup. The Oakland, CA-based firm ...
Moderna revealed the consequences of its late start in the market for RSV vaccines, reporting just $10 million in third-quarter sales from the new shot. Those numbers are a fraction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback